1800-272-662
Shopping Cart 0
countryflagAU
Login

Shuttle Pharmaceuticals Inc

Healthcare US SHPH

0.9086USD
0.02(2.62%)

Last update at 2026-03-11T14:56:00Z

Day Range

0.910.96
LowHigh

52 Week Range

0.351.27
LowHigh

Fundamentals

  • Previous Close 0.89
  • Market Cap7.45M
  • Volume12493
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.72521M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.5

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Income before tax -3.02845M -1.15213M -0.80573M - -
Minority interest - - - - -
Net income -3.09946M -1.20292M -0.84536M - -
Selling general administrative 1.07M 0.72M 0.35M - -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.07M 0.02M 0.02M - -
Ebit -2.55428M -1.74299M -0.50952M -0.58663M -0.33616M
Ebitda -2.15876M -1.68216M -0.45457M - -
Depreciation and amortization 0.40M 0.06M 0.05M - -
Non operating income net other - - - - -
Operating income -2.55428M -1.74299M -0.50952M - -
Other operating expenses 2.55M 1.74M 0.51M - -
Interest expense 0.97M 0.05M 0.04M - 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M - -
Interest income - - - - -
Net interest income -0.96989M -0.05079M -0.03963M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.05M 0.04M - -
Total revenue 0.00000M 0.00000M 0.00000M - -
Total operating expenses 2.55M 1.74M 0.51M - -
Cost of revenue - - - - -
Total other income expense net -0.47417M 0.59M -0.29621M - -
Discontinued operations - - - - -
Net income from continuing ops -3.02845M -1.15213M -0.80573M - -
Net income applicable to common shares -3.09946M -1.25520M -0.90879M -0.62614M -0.34059M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2018-12-31
Total assets 5.95M 8.65M 0.65M 0.54M -
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.11M 0.16M 0.00487M 0.01M 0.25M
Total liab 1.90M 0.98M 2.28M 2.23M -
Total stockholder equity 4.06M 7.68M -1.62813M -1.69030M -
Deferred long term liab - - - - -
Other current liab 0.11M 0.11M 0.09M 0.67M 0.02M
Common stock 0.00016M 0.00014M 0.00009M 0.00009M 0.00018M
Capital stock 0.00016M 0.00014M 0.02M 0.02M -
Retained earnings -15.48761M -8.89489M -5.79543M -4.54024M -1.91059M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00648M 0.00648M 0.00648M 0.00648M
Cash 2.58M 8.42M 0.50M 0.12M -
Cash and equivalents - - - - -
Total current liabilities 1.04M 0.98M 2.22M 2.10M 0.59M
Current deferred revenue - - 0.38M 0.23M -
Net debt -1.48872M -7.66891M 0.47M 0.70M -
Short term debt 0.65M 0.75M 0.92M 0.69M -
Short long term debt 0.60M 0.69M 0.85M 0.63M -
Short long term debt total 1.09M 0.75M 0.98M 0.82M -
Other stockholder equity 19.54M 16.57M 4.17M 2.85M 0.02M
Property plant equipment - 0.07M 0.14M 0.20M 0.00084M
Total current assets 5.59M 8.58M 0.51M 0.34M 0.61M
Long term investments - - - - -
Net tangible assets - 7.68M -1.62813M -1.69030M 0.03M
Short term investments 2.89M - - - -
Net receivables 0.01M - 0.00000M 0.21M 0.00382M
Long term debt 0.14M - - - -
Inventory - - - - -
Accounts payable 0.28M 0.12M 0.83M 0.52M 0.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.00648M 0.00648M 0.00648M -
Deferred long term asset charges - - - - -
Non current assets total 0.36M 0.08M 0.14M 0.20M -
Capital lease obligations 0.36M 0.06M 0.13M 0.19M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2018-12-31 2016-12-31
Investments - 0.00000M -0.01082M - -
Change to liabilities -0.38288M 0.31M -0.05113M -0.04837M 0.00000M
Total cashflows from investing activities - - -0.01082M -0.01082M 0.02M
Net borrowings 0.60M 0.69M 0.07M 0.21M 0.15M
Total cash from financing activities 10.62M 0.69M 0.07M 0.87M 0.17M
Change to operating activities -0.17232M -0.00365M -0.10602M 0.02M 0.06M
Net income -3.02845M -1.15213M -0.80573M -0.62614M -0.34059M
Change in cash 7.91M 0.39M 0.03M 0.30M -0.03604M
Begin period cash flow 0.50M 0.12M 0.08M 0.12M -
End period cash flow 8.42M 0.50M 0.12M 0.08M 0.12M
Total cash from operating activities -2.71045M -0.30034M -0.02683M -0.56669M -0.23007M
Issuance of capital stock 10.02M - - - -
Depreciation 0.07M 0.06M 0.05M 0.02M 0.02M
Other cashflows from investing activities - - - - 0.02M
Dividends paid -0.40207M - - - -
Change to inventory - - - - -
Change to account receivables 0.00000M 0.21M 0.16M 0.05M 0.03M
Sale purchase of stock - - - - -
Other cashflows from financing activities 1.05M 0.69M -0.01082M -0.25000M -
Change to netincome -0.07914M 0.27M 0.72M 0.02M 0.00099M
Capital expenditures 0.00000M 0.00000M 0.01M 0.01M 0.00455M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.55520M 0.52M 0.00778M - -
Stock based compensation 0.40M 0.91M 0.46M - -
Other non cash items 0.40M 0.00339M 0.26M - -
Free cash flow -2.71045M -0.30034M -0.03765M - -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
SHPH
Shuttle Pharmaceuticals Inc		 0.02 2.62% 0.91 - - - 1.70 -0.6188
ZTS
Zoetis Inc		 -1.16 0.96% 119.33 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.02 0.08% 25.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 5.77 4.51% 133.78 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.045 0.25% 18.16 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.

Shuttle Pharmaceuticals Inc

One Research Court, Rockville, MD, United States, 20850

Key Executives

Name Title Year Born
Dr. Anatoly Dritschilo M.D. Co-Founder, MD, CEO & Chairman 1944
Mr. Peter Dale Dritschilo M.B.A., M.D. Pres & COO 1969
Mr. Michael P. Vander Hoek CFO and VP of Operations & Regulatory 1960
Dr. Milton Brown CSC, M.D., Ph.D. Co-Founder, Chief Scientific Officer for Chemistry & Director 1965
Dr. Mira Jung Ph.D. Co-Founder & Chief Scientific Officer for Biology 1949
Mr. Gene Jung Esq. Gen. Counsel NA
Dr. Tyvin A. Rich M.D. Chief Clinical Officer 1949
Dr. Theodore L. Phillips M.D., Ph.D. Clinical Director 1933
Mr. Michael Jeffrey Starkweather VP of Bus. Devel. 1984
Mr. Peter Dale Dritschilo M.B.A., M.D. President & COO 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.